- Home
- AAMI vs AGIO Comparison
AAMI vs AGIO Comparison
Compare AAMI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | AGIO |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | AAMI | AGIO |
|---|---|---|
| Price | $47.67 | $26.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $43.50 | $32.13 |
| AVG Volume (30 Days) | 231.8K | ★ 2.7M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.08% | N/A |
| EPS Growth | ★ 45.00 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $559,300,000.00 | $44,791,000.00 |
| Revenue This Year | $17.88 | $28.75 |
| Revenue Next Year | $21.58 | $139.45 |
| P/E Ratio | $19.89 | ★ N/A |
| Revenue Growth | 19.25 | ★ 36.26 |
| 52 Week Low | $22.60 | $22.24 |
| 52 Week High | $54.99 | $46.00 |
Technical Indicators
Market Signals| Indicator | AAMI | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 34.93 |
| Support Level | $45.67 | $26.80 |
| Resistance Level | $49.38 | $28.61 |
| Average True Range (ATR) | 1.56 | 1.17 |
| MACD | 0.46 | 0.26 |
| Stochastic Oscillator | 72.45 | 5.65 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.